NEW YORK, June 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 6:
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date | Index Name | Action | Company Name | Ticker | GICS Sector |
July 3, 2023 | S&P 500 | Addition | Fortrea Holdings | FTRE | Health Care |
July 5, 2023 | S&P 500 | Addition | PHINIA | PHIN | Consumer Discretionary |
July 6, 2023 | S&P 500 | Deletion | Fortrea Holdings | FTRE | Health Care |
July 6, 2023 | S&P 500 | Deletion | PHINIA | PHIN | Consumer Discretionary |
July 6, 2023 | S&P SmallCap 600 | Addition | Fortrea Holdings | FTRE | Health Care |
July 6, 2023 | S&P SmallCap 600 | Addition | PHINIA | PHIN | Consumer Discretionary |
July 6, 2023 | S&P SmallCap 600 | Deletion | Seneca Foods | SENEA | Consumer Staples |
July 6, 2023 | S&P SmallCap 600 | Deletion | El Pollo Loco Holdings | LOCO | Consumer Discretionary |
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
FOR MORE INFORMATION:
S&P Dow Jones Indices
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$259.12 |
Daily Change: | -0.88 -0.34 |
Daily Volume: | 144,909 |
Market Cap: | US$21.670B |
April 29, 2025 April 02, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load